AF 130

Drug Profile

AF 130

Alternative Names: AF-130

Latest Information Update: 03 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Merck & Co
  • Class Analgesics; Antihypertensives; Heart failure therapies; Small molecules
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hypertension; Migraine

Most Recent Events

  • 18 May 2016 Afferent Pharmaceuticals completes a phase I trial in healthy volunteers in USA (NCT02652936)
  • 18 May 2016 Afferent Pharmaceuticals plans a phase II trial for Hypertension in USA
  • 08 Dec 2015 Phase-I clinical trials in Hypertension in United Kingdom (PO) (NCT02652936)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top